Sanofi: Jefferies still a buyer
(CercleFinance.com) - Jefferies maintains its buy rating on the share, with a target price of 110 euros (27% upside).
The broker expects EPS growth of 3-5% from 2022 onwards, mainly due to cost reductions and the implementation of new, more efficient procedures.
Jefferies remains optimistic about the group's main growth drivers, Dupixent and flu vaccines.
For example, it estimates that sales of Dupixent as an asthma treatment could increase from 460 million euros in 2020 to 2.9 billion euros in 2028.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The broker expects EPS growth of 3-5% from 2022 onwards, mainly due to cost reductions and the implementation of new, more efficient procedures.
Jefferies remains optimistic about the group's main growth drivers, Dupixent and flu vaccines.
For example, it estimates that sales of Dupixent as an asthma treatment could increase from 460 million euros in 2020 to 2.9 billion euros in 2028.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.